Cancer Research

Rexahn Pharmaceuticals' oncology candidate, RX-0201, shows limited side effect profile

Published in Cancer Weekly, March 14th, 2006

Rexahn Pharmaceuticals (RXHN) announced the status of phase I clinical trials of one of its leading oncology candidates, RX-0201 that showed at 192 mg/M², patients showed no dose limiting toxicity.

RX-0201 is a first-in-class signal inhibitor that directly blocks the production of Akt, a protein kinase, playing a key role in cancer progression.

The trial, which is ongoing at Georgetown University and the University of Alabama, is designed to determine the safety and tolerability of RX-0201 in patients with cancer. The trial protocol calls for patients to undergo two cycles of 2 weeks on the drug and 1 week off. At 192 mg/M²,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-03-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry